Phoenixville, Pennsylvania, USA, November 10, 2026
Bechtel Medical, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its flagship wound-care product, Wound VOX™, a system combining negative pressure wound therapy (NPWT) and topical oxygen therapy (TOT) in a single platform. The company announced the regulatory milestone on November 10, 2026, describing Wound VOX as the first 510(k)-cleared system to combine these two therapeutic capabilities. The device is designed for the advanced wound-care sector, particularly the management of complex wounds that may require specialized treatment approaches. By bringing negative pressure and topical oxygen delivery together, Bechtel Medical aims to simplify the operational demands associated with using separate wound-care technologies. The company plans a limited commercial release in December 2026, marking the next stage in bringing the cleared system to clinicians and the wound-care market.
Wound VOX Combines Negative Pressure and Topical Oxygen
Wound VOX incorporates three operating modes: continuous negative pressure wound therapy, intermittent negative pressure wound therapy, and intermittent negative pressure wound therapy with adjunctive topical oxygen therapy. Negative pressure wound therapy is an established approach used in advanced wound management. It applies controlled sub-atmospheric pressure to a wound through a specialized dressing and connected system. The treatment is used in different complex wound-care settings, with the specific clinical approach determined by the wound characteristics and patient needs. Topical oxygen therapy, meanwhile, delivers oxygen directly to the wound environment. Oxygen plays an important role in normal tissue repair processes, including cellular metabolism, collagen formation and other mechanisms involved in healing. Bechtel Medical developed Wound VOX to integrate these two approaches within one system, rather than requiring clinicians to manage separate devices for negative pressure and topical oxygen treatment. According to the company, this integrated design is intended to reduce operational complexity and support the delivery of advanced wound care. The three operating modes provide different treatment configurations, allowing the system to deliver negative pressure alone or combine it with topical oxygen. The company believes that bringing the technologies together could help address practical and economic barriers that have historically affected access to these treatment approaches.
Research Supports Interest in Combination Wound Therapy
The announcement also highlights independent research examining the potential benefits of combining negative pressure wound therapy with topical oxygen. A 2025 systematic review and meta-analysis published in Advances in Wound Care, conducted by Su and colleagues, evaluated 11 randomized controlled trials involving combination treatment approaches. The review reported significantly higher complete wound-healing rates and lower bacterial positivity rates with combination therapy compared with negative pressure wound therapy alone. These findings provide scientific context for the interest in integrating the two treatment approaches in advanced wound management. However, it is important to distinguish the published research from evidence specifically generated using Wound VOX. The studies included in the review evaluated combination treatment approaches and were not clinical trials of Bechtel Medical’s Wound VOX system. Therefore, the findings should not be interpreted as proof that Wound VOX itself produces the same outcomes. Further device-specific clinical evidence and real-world experience will be important in understanding its performance, safety and role in wound-care practice. The company’s announcement focuses on the FDA clearance and the system’s integrated design rather than presenting new clinical trial results for the device.
Advertisement
FDA Clearance Marks Next Step Toward Commercial Launch
Commenting on the clearance, John Gvodas, Founder and Chief Executive Officer of Bechtel Medical, said that treating difficult-to-heal wounds with negative pressure and concentrated oxygen has traditionally required clinicians to manage separate systems. He explained that the company designed Wound VOX to integrate the two technologies into one platform, with the aim of simplifying advanced wound-care delivery and addressing operational and economic challenges. Bechtel Medical, based in Phoenixville, Pennsylvania, designs, develops and manufactures wound-care devices and dressings. Its work focuses on technologies intended to address clinical needs in the advanced wound-care sector while emphasizing product quality, engineering and patient safety. Following the FDA 510(k) clearance, the company plans to begin a limited commercial release in December 2026. Clinicians and potential durable medical equipment distribution partners are among the groups the company expects to engage as it moves toward market introduction. The regulatory milestone gives Wound VOX a pathway toward commercialization in the United States, while its planned release will provide an opportunity for healthcare professionals to evaluate the integrated system in clinical practice. The development also reflects continued innovation in wound-care technology, where device integration may help streamline treatment workflows. As the product enters the market, its clinical utility will depend on appropriate use, patient selection and evidence gathered through its use in wound-management settings.
Source: Bechtel Medical press release
